Intra-abdominal fungal infections

Current Opinion in Infectious Diseases

Volumn 26, Issue 5, 2013, Pages 441-446

  Rebolledo, Mauricio ^a   Sarria, Juan C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Candida; fungal infections; intra abdominal; peritonitis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ABDOMINAL INFECTION; ASCITES FLUID ANALYSIS; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CLINICAL PRACTICE; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DISEASE PREDISPOSITION; HISTOPLASMOSIS; HUMAN; IMMUNE STATUS; MUCORMYCOSIS; MYCOSIS; PERITONEAL DIALYSIS; PERITONITIS; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; HUMANS; INTRAABDOMINAL INFECTIONS; MYCOSES;

EID: 84883597390     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000433309.21148.f7     Document Type: Review

References (41)

1. Infectious Diseases Society of America. Clinical practice guidelines. Infections by organism. http://www.idsociety.org/Organism/. [Accessed 3 May 2013].
2. Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses 2012; 55:e74-e84.
3. De Castro N, Mazoyer E, Porcher R, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris. Clin Microbiol Infect 2012; 18:E185-E187.
4. Pappas PG, Kauffman CA, Andes D, et al. Clinical Practice Guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
5. Bayram C, Fettah A, Yarali N, et al. Adjuvant corticosteroid therapy in hepatosplenic candidiasis-related iris. Mediterr J Hematol Infect Dis 2012; 4:e2012018.
6. Carneiro HA, Mavrakis A, Mylonakis E. Candida peritonitis: an update on the latest research and treatments. World J Surg 2011; 35:2650-2659.
7. Ubeda A, Vázquez AL, Gil CL. [Candida peritonitis]. Enferm Infecc Microbiol Clin 2010; 28 (Suppl. 2):42-48.
8. Montravers P, Mira JP, Gangneux JP, et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 2011; 17:1061-1067.
9. Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. Perit Dial Int 2009; 29 (Suppl. 2):S161-S165.
10. Levallois J, Nadeau-Fredette AC, Labbé AC, et al. Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. Int J Infect Dis 2012; 16:e41-e43.
11. Miles R, Hawley CM, McDonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009; 76:622-628.
12. Lenz P, Conrad B, Kucharzik T, et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study. Gastrointest Endosc 2009; 70:480-487.
13. Diebel LN, Raafat AM, Dulchavsky SA, Brown WJ. Gallbladder and biliary tract candidiasis. Surgery 1996; 120:760-764.
14. Bozzette SA, Gordon RL, Yen A, et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis 1992; 15:701-703.
15. Goicoechea M, Fierer J, Johns S. Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: documentation of biliary excretion of caspofungin. Clin Infect Dis 2004; 38:1040-1041.
16. Trikudanathan G, Navaneethan U, Vege SS. Intra-abdominal fungal infections complicating acute pancreatitis: a review. Am J Gastroenterol 2011; 106: 1188-1192.
17. Vege SS, Gardner TB, Chari ST, et al. Outcomes of intra-abdominal fungal vs. bacterial infections in severe acute pancreatitis. Am J Gastroenterol 2009; 104:2065-2070.
18. Hoerauf A, Hammer S, Mü ller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26:2010-2015.
19. Hori A, Kami M, Kishi Y, et al. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002; 50:175-182.
20. Eggimann P, Chevrolet JC, Starobinski M, et al. Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection 2006; 34:333-338.
21. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
22. Erdman SH, Barber BJ, Barton LL. Aspergillus cholangitis: a late complication after Kasai portoenterostomy. J Pediatr Surg 2002; 37:923-925.
23. Nannini EC, Paphitou NI, Ostrosky-Zeichner L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003; 46:49-54.
24. Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (NY) 2012; 8:140-142.
25. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
26. Ismail MH, Hodkinson HJ, Setzen G, et al. Gastric mucormycosis. Trop Gastroenterol 1990; 11:103-105.
27. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20:581-607.
28. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-509.
29. Sedlacek M, Cotter JG, Suriawinata AA, et al. Mucormycosis peritonitis: more than 2 years of disease-free follow up after posaconazole salvage therapy after failure of liposomal amphotericin B. Am J Kidney Dis 2008; 51:302-306.
30. Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993; 17:736-741.
31. Mabee CL, Mabee SW, Kirkpatrick RB, et al. Cirrhosis: a risk factor for cryptococcal peritonitis. Am J Gastroenterol 1995; 11:2042-2045.
32. Singh N, Husain S, de Vera M, et al. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 2004; 83:188-192.
33. Albert-Braun S, Venema F, Bausch J, et al. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection 2005; 33:282-288.
34. Goodwin RA Jr, Shapiro JL, Thurman GH, et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore) 1980; 59:1-33.
35. Kahi CJ, Wheat LJ, Allen SD, Sarosi GA. Gastrointestinal histoplasmosis. Am J Gastroenterol 2005; 100:220-231.
36. Cappell MS, Mandell W, Grimes MM, Neu HC. Gastrointestinal histoplasmosis. Dig Dis Sci 1988; 33:353-360.
37. Abu Al Rub F, Whitt K, Tombazzi C. Disseminated histoplasmosis presenting with biliary obstruction and duodenal ulcer. Tenn Med 2009; 102:45-46.
38. Kapelusznik L, Arumugam V, Caplivski D, Bottone EJ. Disseminated histoplasmosis presenting as AIDS cholangiopathy. Mycoses 2011; 54:262-264.
39. Phillips P, Ford B. Peritoneal coccidioidomycosis: case report and review. Clin Infect Dis 2000; 30:971-976.
40. Smith G, Hoover S, Sobonya R, et al. Abdominal and pelvic coccidioidomycosis. Am J Med Sci 2011; 341:308-311.
41. Ampel NM, White J, Varanasi U, et al. Coccidioidal peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1988; 11:512-514.